NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026 - NeoGenomics ( NASDAQ:NEO )
NeoGenomics NEO is in Phase 18, the final stage of its Adhishthana Cycle on the weekly charts. After more than 850 days of consolidation, the stock shows little sign of breaking out.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO - NeoGenomics ( NASDAQ:NEO )
NEW YORK, Sept. 06, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ( "NeoGenomics" or the "Company" ) NEO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday - Ameresco ( NYSE:AMRC ) , Affiliated Managers Group ( NYSE:AMG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Guggenheim raised Inventiva S.A. IVA price target from $9 to $13. Guggenheim analyst Etzer Darout ...
Why Is NeoGenomics Stock Soaring Friday - Natera ( NASDAQ:NTRA )
Court invalidates certain Natera patents, clearing NeoGenomics' RaDaR ST assay for commercialization. William Blair says launch could come in Q4 2025; maintains Market Perform rating. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special )
Affirm Posts Better-Than-Expected Earnings, Joins Ambarella, IREN, Petco Health and Wellness And Other Big Stocks Moving Higher On Friday - Autodesk ( NASDAQ:ADSK ) , Affirm Holdings ( NASDAQ:AFRM )
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Friday. Shares of Affirm Holdings, Inc. AFRM gained 20.1% to $96.10 after the company reported better-than-expected quarterly EPS and sales. Affirm reported quarterly earnings of 20 cents per share, which beat the Street ...
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
TEM accelerates its healthcare edge with Paige, Deep 6 AI, and Ambry Genetics acquisitions, expanding data, tech and clinical reach.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO - NeoGenomics ( NASDAQ:NEO )
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ( "NeoGenomics" or the "Company" ) NEO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO - NeoGenomics ( NASDAQ:NEO )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ( "NeoGenomics" or the "Company" ) NEO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO - NeoGenomics ( NASDAQ:NEO )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ( "NeoGenomics" or the "Company" ) NEO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO - NeoGenomics ( NASDAQ:NEO )
NEW YORK, Aug. 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ( "NeoGenomics" or the "Company" ) NEO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Down 29.2% in 4 Weeks, Here's Why NeoGenomics ( NEO ) Looks Ripe for a Turnaround
NeoGenomics (NEO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Fulcrum Therapeutics ( NASDAQ:FULC ) , Exelixis ( NASDAQ:EXEL )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday. Shares of Whirlpool Corporation WHR fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 earnings guidance.
NeoGenomics ( NEO ) Meets Q2 Earnings Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -0.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Amicus Therapeutics ( FOLD ) to Report a Decline in Earnings: What to Look Out for
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out - Guardant Health ( NASDAQ:GH ) , Quest Diagnostics ( NYSE:DGX ) , Exact Sciences ( NASDAQ:EXAS ) , Labcorp Hldgs ( NYSE:LH )
BofA raised Tempus AI's price forecast to $70 but maintained a Neutral rating due to valuation concerns. Guardant Health, Exact Sciences, and LabCorp received Buy ratings for AI-aligned precision medicine strategies. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Gap ( NYSE:GAP ) , NeoGenomics ( NASDAQ:NEO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday - AtriCure ( NASDAQ:ATRC ) , Airbnb ( NASDAQ:ABNB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised Visa Inc. V price target from $383 to $384.
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings - Hims & Hers Health ( NYSE:HIMS ) , Leggett & Platt ( NYSE:LEG )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 250 points on Tuesday. The Dow traded up 0.70% to 40,507.41 while the NASDAQ rose 0.30% to 17,417.49. The S&P 500 also rose, gaining, 0.37% to 5,548.98. Materials shares jumped by 0.6% on Monday.
NeoGenomics ( NEO ) Reports Break-Even Earnings for Q1
NeoGenomics (NEO) delivered earnings and revenue surprises of 100% and 1.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
The Proxies 2024: Where are they now?
Perk it out ...
Analysts Estimate GSK ( GSK ) to Report a Decline in Earnings: What to Look Out for
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics ( NEO ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.
NeoGenomics ( NEO ) Tops Q4 Earnings Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 100% and 0.92%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
PacBio Announces Appointment of Chris Smith to Board of Directors - Pacific Biosciences ( NASDAQ:PACB ) , NeoGenomics ( NASDAQ:NEO )
MENLO PARK, Calif., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- PacBio PACB, a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of ...
PacBio Announces Appointment of Chris Smith to Board of Directors
PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down.
Adaptive Biotechnologies ( ADPT ) Soars 18.0%: Is Further Upside Left in the Stock?
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
NeoGenomics ( NEO ) Surges 9.1%: Is This an Indication of Further Gains?
NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients - Adaptive Biotechnologies ( NASDAQ:ADPT ) , NeoGenomics ( NASDAQ:NEO )
SEATTLE and FORT MYERS, Fla., Jan. 14, 2025 ( GLOBE NEWSWIRE ) -- Adaptive Biotechnologies Corporation ADPT, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc.
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART ...
NeoGenomics Shares Are Falling Today: What's Going On? - NeoGenomics ( NASDAQ:NEO )
NeoGenomics shares dropped 19.4% after announcing CEO Chris Smith's retirement, with Tony Zook. While Zook brings significant healthcare leadership experience, investors are cautious about the impact of the transition. Get Real-Time News and Alerts for Your Portfolio Shares of NeoGenomics, Inc.
NeoGenomics ( NEO ) Upgraded to Buy: Here's Why
NeoGenomics (NEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology
Westford, USA, Nov. 22, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Gene Panel Market share will reach a value of USD 11.75 Billion by 2031, with a CAGR of 19.30% during the forecast period ( 2024-2031 ) .
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer ( SITC ) Annual Meeting
BOSTON, Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled "Pharmacodynamic and Response Biomarkers in ...
NeoGenomics ( NEO ) Upgraded to Strong Buy: Here's What You Should Know
NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts Believe NeoGenomics ( NEO ) Could Rally 51.29%: Here's is How to Trade
The consensus price target hints at a 51.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NeoGenomics ( NEO ) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
NeoGenomics (NEO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday - PayPal Holdings ( NASDAQ:PYPL )
U.S. stocks were mixed, with the Dow Jones index gaining more than 100 points on Tuesday. Shares of PayPal Holdings, Inc. PYPL rose sharply during Tuesday's session after the company reported better-than-expected second quarter financial results.
Bioinformatics Market to Gain USD 45.6 Billion by 2031 | SkyQuest
Westford, USA, July 23, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that Global Bioinformatics Market will attain a value of USD 45.6 Billion by 2031, with a CAGR of 16.3% over the forecast period ( 2024-2031 ) .
Billionaire Groupon Founder Eric Lefkofsky's Health Tech Company Goes Public-His Fourth IPO
ive years ago, Chicago-based billionaire and serial entrepreneur Eric Lefkofsky told Forbes he hoped health analytics and precision medicine company Tempus AI would be his "legacy project." It's currently his most valuable asset-and his fourth company to go public.
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Michael Dent, Chairman & CEO of HealthLynked Corp. - HealthLynked ( OTC:HLYK )
LOS ANGELES, June 12, 2024 ( GLOBE NEWSWIRE ) -- via IBN - IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to ...
Bioinformatics Market size is set to grow by USD 8535.52 mn from 2023-2027, reduction in cost of genetic sequencing ... - PR Newswire
Bioinformatics Market size is set to grow by USD 8535.52 mn from 2023-2027, reduction in cost of genetic sequencing ... PR ...
NeoGenomics ( NEO ) Reports Q1 Loss, Tops Revenue Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 33.33% and 4.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Myriad Genetics ( MYGN ) Report Negative Q1 Earnings? What You Should Know
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics ( NEO ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Absci Corporation ( ABSI ) Moves 16.8% Higher: Will This Strength Last?
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Anatomic Pathology Market Size is projected to reach USD 45.27 billion by 2031, growing at a CAGR of 9.88%: Straits Research
New York, United States, April 02, 2024 ( GLOBE NEWSWIRE ) -- Anatomic pathology is a broad field that includes subdomains such as cytopathology, gastrointestinal pathology, gynecological pathology, musculoskeletal pathology, renal pathology, dermatopathology and immunohistochemistry, in-situ ...
All You Need to Know About NeoGenomics ( NEO ) Rating Upgrade to Buy
NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does NeoGenomics ( NEO ) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 29.57% Upside in NeoGenomics ( NEO ) : Here's What You Should Know
The consensus price target hints at a 29.6% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
